Proteomics of TGF-beta signaling and its impact on breast cancer

Serhiy Souchelnytskyi1

  • 1Uppsala University, Ludwig Institute for Cancer Research, Box 595, SE-75124, Uppsala, Sweden. serhiy.souchelnytskyi@licr.uu.se

Expert Review of Proteomics
|November 26, 2005
PubMed

Insights

Large-scale proteomics studies reveal complex cancer mechanisms. Understanding transforming growth factor-beta (TGF-beta) signaling in breast cancer advances novel therapeutic strategies.

Area of Science:

  • Oncology and Molecular Biology
  • Proteomics and Cancer Signaling

Background:

  • Cancer progression involves complex molecular mechanisms, necessitating large-scale studies like proteomics.
  • Transforming growth factor-beta (TGF-beta) exhibits dual roles in cancer, inhibiting early tumor growth but promoting later-stage metastasis.

Purpose of the Study:

  • To review recent advances in proteomics studies of TGF-beta signaling in breast cancer.
  • To elucidate the contribution of TGF-beta signaling to breast tumorigenesis and treatment.

Main Methods:

  • Utilizing proteomics to monitor thousands of proteins simultaneously.
  • Analyzing TGF-beta-dependent regulation of key cellular processes including proliferation, apoptosis, DNA repair, and transcription.

Main Results:

  • Proteomics has significantly expanded the understanding of TGF-beta's role in breast cancer.
  • Identified novel signaling mechanisms contributing to tumorigenesis.

Conclusions:

  • Enhanced understanding of TGF-beta signaling pathways in breast cancer.
  • Opens avenues for developing novel anticancer treatments and drugs targeting TGF-beta pathways.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...